Tempus
Tempus's full profile: funding, valuation, competitors, and the people behind the company.
Updated Mar 23, 2026Awaira Score
Out of 100
HQ
United States
Founded
2015
Raised
$1.05B
Stage
Public
Team
2500
Valuation
$8.1B
Post-money
Total Raised
$1.05B
All rounds
Awaira Score
84/100
Founded
2015
2500 employees
Awaira estimate based on public data. Not financial advice.
About Tempus
Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial…
Is this your company? Claim it →Strengths & Risks
Strengths
Raised over $1.05B — one of the best-funded AI companies
Unicorn status with $8.1B valuation
Elite Awaira Score of 84/100
Analysis based on publicly available data. Not investment advice.
Market Position
Tempus is a AI unicorn in the AI Healthcare sector. Founded in 2015, the company is currently at the Public stage with a team of approximately 2500 employees. With $1.05B in total disclosed funding, Tempus has demonstrated the ability to attract institutional capital. The company competes with 3 other tracked AI Healthcare companies on Awaira, including Butterfly Network and Alan.
Key Numbers
Awaira Score
84/100
Valuation
$8.1B
Total Funding
$1.05B
Founded
2015
Employees
2500
Stage
Public
Funding Velocity
5
Total Rounds
$90M
Avg Round Size
5.6yr
Funding Span
Tempus raised 5 rounds over 5.6 years, averaging $90M per round — a pace of roughly one round every 13 months.
Why Track Tempus?
Tempus holds unicorn status in the AI Healthcare space, placing it among the highest-valued private AI companies globally.
Among 3 tracked competitors, Tempus ranks #1 by valuation — a metric investors and analysts use to gauge market standing.
Tracking Tempus on Awaira provides real-time updates on funding rounds, investor activity, and competitive moves in the AI Healthcare market.
Competitor Comparison
| Metric | ★Tempus | Butterfly Network | Alan | Abridge |
|---|---|---|---|---|
| Awaira Score | 84/100 | 85/100 | 83/100 | 76/100 |
| Total Raised | $1.05B | $370M | $750M | $800M |
| Valuation | $8.1B | $957M | $5.83B | $5.3B |
| Stage | Public | Public | Series D | Series E |
| Founded | 2015 | 2011 | 2016 | 2018 |
| Employees | 2500 | 500-1000 | 500-1000 | 120 |
| Country | 🇺🇸 | 🇺🇸 | 🇫🇷 | 🇺🇸 |
Funding Rounds
InactiveUndisclosed
Jul 2021
$175M
Jan 2021
$110M
Jan 2019
$45M
Jan 2017
$30M
Jan 2016
Open Positions at Tempus
View all jobs →Tempus Latest News
GE Ventures Portfolio Company Tempus Sees AI-Driven Growth in Healthcare
Tempus AI Goes Public in $6.1 Billion IPO
Tempus Launches Next-Generation AI Capabilities for Enterprise Customers
Tempus Partners with Pathos AI to Expand AI-Driven Cancer Diagnostics
Compare Tempus
See how Tempus stacks up against competitors in valuation, funding, team size, and Awaira Score.
Founded Same Year (2015)
Similar by Funding Stage (Public)
More from United States
🇺🇸 View all AI companies in United States →Alternatives
View all alternatives to Tempus →